Endocrine therapy: defining the path of least resistance by Andrew Stone & Elizabeth A Musgrove
Stone and Musgrove Breast Cancer Research 2014, 16:101
http://breast-cancer-research.com/content/16/3/101EDITORIALEndocrine therapy: defining the path of least
resistance
Andrew Stone1 and Elizabeth A Musgrove2*
See related research by Beelen et al. http://breast-cancer-research.com/content/16/1/R6, http://breast-cancer-research.com/content/16/1/R13,
and by Lin et al., http://breast-cancer-research.com/content/15/6/R119Abstract
One of the best-characterized oncogenic mechanisms
in breast cancer is the aberrant activation of
phosphatidylinositol-3-kinase, protein kinase B, and
mammalian target of rapamycin signaling. In both
endocrine-resistant disease and breast cancer stem cells,
this is commonly caused by specific genetic lesions or
amplification of key pathway components or both.
These observations have generated two interesting
hypotheses. Firstly, do these genetic anomalies provide
clinically significant biomarkers predictive of endocrine
resistance? Secondly, do tamoxifen-resistant breast
cancer cells emerge from a stem-like cell population?
New studies, published in Breast Cancer Research, raise the
possibility that these hypotheses are intrinsically linked.determining region Y-box, E2F transcription factor, andIn experimental models of estrogen receptor (ER)-positive
breast cancer, the hyperactivation of phosphatidylinositol-3-
kinase (PI3K), protein kinase B (AKT), and mammalian tar-
get of rapamycin (mTOR) can impede the inhibitory effect
of endocrine therapy. This hyperactivation can be caused
by augmented growth factor signaling, inactivation of
PI3K inhibitors such as phosphatase and tensin homologue,
and mutation and/or amplification of PI3K subunits
and activators. Although these aberrations are frequently
observed in human breast cancer, their clinical significance
in endocrine-resistant disease remains controversial. Recent
studies by Beelen and colleagues [1,2] and Lin and
colleagues [3] in Breast Cancer Research raise the possibility
that heterogeneity between different breast cancer cell
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article, unless otherwise stated.Breast cancer stem cells (BCSCs) commonly harbor gain-
of-function mutations in key components of the PI3K/AKT/
mTOR signaling pathway [4,5]. For example, mutations in
PIK3CA, a gene encoding a catalytic subunit of PI3K, were
recently reported to be present in 8 out of 11 BCSC popula-
tions extracted from breast cancer specimens but absent in
normal mammary stem cells [4]. It is thought that such
attributes facilitate BCSC characteristics such as drug
resistance and tumor progression [5]. A growing body of
evidence suggests that endocrine-resistant breast cancer
cells may be derived from a stem-like cell population [3,6].
By interrogating the genetic and epigenetic profiles of
multiple tamoxifen-resistant cell lines, Lin and colleagues
[3] determined that both intrinsic and acquired resistance
were strongly associated with the deregulation of genes
related to pluripotency and differentiation, including sex-
retinoblastoma gene product family pocket proteins. This
suggests that resistant cells could emerge from discrete
populations of stem-like breast cancer cells. Because as few
as 100 BCSCs were able to form tumors in mice, whereas
tens of thousands of cells with alternative phenotypes failed
to form tumors [7], it is apparent that endocrine-resistant
BCSCs may represent a very small needle in a very large
haystack. It is therefore questionable whether molecular bio-
markers associated with this cell phenotype could be readily
detectable in primary disease for diagnostic purposes.
Much controversy surrounds the clinical significance of
PI3K/AKT/mTOR-associated biomarkers in breast cancer.
Some reports, including that of Beelen and colleagues [2],
suggest that PIK3CA mutation is associated with a longer
disease-free survival, lower tumor grade, and increased ER
expression [2,8,9], whereas others report an association
with poor survival rates [10] (recently reviewed in [11]). Im-
portantly, unlike other investigators, Beelen and colleagues
[2] were able to examine whether these mutations were
specifically associated with response to tamoxifen but didCentral Ltd. This is an Open Access article distributed under the terms of the
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tamoxifen treatment and PI3KA mutation. It would be
interesting, based on the results of Lin and colleagues [3],
to determine whether the same was true if PI3KA mutation
rates were measured in BCSCs derived from the clinical
trial cohorts used by Beelen and colleagues, although this is
unlikely to be practicable.
Why would a PIK3CA mutation be predictive in some
breast cancer cell types but not others? Stem cells have a
greater propensity to accumulate genetic and epigenetic
modifications in order to acquire a survival advantage when
under selection pressure [12]. This phenomenon is further
evidenced by the demonstration that emergent ‘stem-like’
resistant populations featured methylomic modifications to
gene promoter regions associated with reduced expression
of genes that conferred survival [3]. With the emergence of
epigenetic biomarkers across multiple aspects of breast
cancer research, this highlights a potential use for DNA
methylation biomarkers as predictors of tamoxifen response
with prospective application in neo-adjuvant studies, as
discussed previously [13].
Biomarkers downstream of PI3K/AKT/mTOR signaling
may reflect pathway activation more accurately than acti-
vating mutations, since the effects of active signaling will be
amplified across the entire tumor cell population through
paracrine growth factor receptor pathways. In agreement
with this idea, Beelen and colleagues [1] demonstrated that
p-p70S6K, a phosphorylation target of mTOR, was predict-
ive of tamoxifen resistance in post-menopausal patients
with breast cancer but was associated with favorable prog-
nosis in patients from the same clinical trial who did not
receive tamoxifen. One could perhaps hypothesize that
there exists a mechanism by which residual ER signaling
limits the expansion of a BCSC population, similar to that
previously shown to regulate neural stem cells [14]. In
patients who received tamoxifen, inhibiting such regulation,
or indeed the acquired genetic and epigenetic changes that
are accumulated by residual breast cancer cells, could then
positively select for a more aggressive cell phenotype,
as previously suggested in experimental models [3,13].
Irrespective of the mechanistic basis for the predictive
power of p-p70S6K, as suggested by Beelen and colleagues,
p-p70S6K may provide a useful companion biomarker for
the mTOR inhibitor, everolimus, which has recently been
approved in Europe and the US in combination with endo-
crine therapy for the treatment of post-menopausal women
with endocrine-resistant disease [15].
Although our understanding of the origins of endocrine-
resistant breast cancer is constantly evolving, it is obvious
that the mechanisms that determine resistance are diverse,
complex, and dynamic. Endocrine-resistant disease still
represents one of the most challenging obstacles in breast
cancer treatment. The appropriate use of PI3K/AKT/
mTOR signaling pathway inhibitors remains to be refinedin endocrine resistance; however, clinical trials suggest that
their clinical impact will be considerable. To maximize
their therapeutic potential, it is critical that companion
biomarkers of response be further characterized.
Abbreviations
AKT: Protein kinase B; BCSC: Breast cancer stem cell; ER: Estrogen receptor;
mTOR: mammalian target of rapamycin; PI3K: Phosphatidylinositol-3-kinase;
PIK3CA: Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit
alpha; p-p70S6K: Phosphorylated p70S6 kinase.
Competing interests
The authors declare that they have no competing interests.
Acknowledgments
AS is supported by the National Breast Cancer Foundation, Australia.
Author details
1Cancer Epigenetics Program, Garvan Institute of Medical Research, 384
Victoria Street, Darlinghurst, Sydney 2010 NSW, Australia. 2Wolfson Wohl
Cancer Research Centre, University of Glasgow, Garscube Estate, Switchback
Road, Glasgow, Bearsden G61 1QH, Scotland.
Published: 22 May 2014
References
1. Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Wesseling J, Muris JJ,
Berns EM, Vermorken JB, van Diest PJ, Linn SC: Phosphorylated p-70S6K
predicts tamoxifen resistance in postmenopausal breast cancer patients
randomized between adjuvant tamoxifen versus no systemic treatment.
Breast Cancer Res 2014, 16:R6.
2. Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Wesseling J, Muris JJ,
Berns EM, Vermorken JB, van Diest PJ, Linn SC: PIK3CA mutations, phosphatase
and tensin homolog, human epidermal growth factor receptor 2, and
insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in
postmenopausal breast cancer patients. Breast Cancer Res 2014, 16:R13.
3. Lin X, Li J, Yin G, Zhao Q, Elias D, Lykkesfeldt AE, Stenvang J, Brünner N, Wang J,
Yang H, Bolund L, Ditzel HJ: Integrative analyses of gene expression and DNA
methylation profiles in breast cancer cell line models of tamoxifen-resistance
indicate a potential role of cells with stem-like properties. Breast Cancer Res
2013, 15:R119.
4. Pommier SJ, Hernandez A, Han E, Massimino K, Muller P, Diggs B, Chamberlain E,
Murphy J, Hansen J, Naik A, Vetto J, Pommier RF: Fresh surgical specimens yield
breast stem/progenitor cells and reveal their oncogenic abnormalities.
Ann Surg Oncol 2012, 19:527–535.
5. Donovan CA, Pommier RF, Schillace R, O’Neill S, Muller P, Alabran JL, Hansen JE,
Murphy JA, Naik AM, Vetto JT, Pommier SJ: Correlation of breast cancer axillary
lymph node metastases with stem cell mutations. JAMA Surg 2013,
148:873–878.
6. O’Brien CS, Farnie G, Howell SJ, Clarke RB: Breast cancer stem cells and their
role in resistance to endocrine therapy. Horm Cancer 2011, 2:91–103.
7. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective
identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003,
100:3983–3988.
8. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV,
Traina TA, Solit D, Gerald W, Moynahan ME: PIK3CA mutation associates with
improved outcome in breast cancer. Clin Cancer Res 2009, 15:5049–5059.
9. Perez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskjold B, Rutqvist LE,
Skoog L, Stal O: PIK3CA mutations and PTEN loss correlate with similar
prognostic factors and are not mutually exclusive in breast cancer.
Clin Cancer Res 2007, 13:3577–3584.
10. Li SY, Rong M, Grieu F, Iacopetta B: PIK3CA mutations in breast cancer are
associated with poor outcome. Breast Cancer Res Treat 2006, 96:91–95.
11. Zardavas D, Phillips W, Loi S: PIK3CA mutations in breast cancer: reconciling
findings from preclinical and clinical data. Breast Cancer Res 2014, 16:201.
12. Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer
2005, 5:275–284.
Stone and Musgrove Breast Cancer Research 2014, 16:101 Page 3 of 3
http://breast-cancer-research.com/content/16/3/10113. Stone A, Valdes-Mora F, Clark SJ: Exploring and exploiting the aberrant DNA
methylation profile of endocrine-resistant breast cancer. Epigenomics 2013,
5:595–598.
14. Brannvall K, Korhonen L, Lindholm D: Estrogen-receptor-dependent regulation
of neural stem cell proliferation and differentiation. Mol Cell Neurosci 2002,
21:512–520.
15. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S,
Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A,
Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN:
Everolimus in postmenopausal hormone-receptor–positive advanced breast
cancer. N Engl J Med 2012, 366:520–529.
doi:10.1186/bcr3659
Cite this article as: Stone and Musgrove: Endocrine therapy: defining the
path of least resistance. Breast Cancer Research 2014 16:101.
